{
    "nct_id": "NCT03522246",
    "official_title": "ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy)",
    "inclusion_criteria": "* Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.\n* Completed cytoreductive surgery, including at least a bilateral salpingo-oophorectomy and partial omentectomy, either prior to chemotherapy (primary surgery) or following neoadjuvant chemotherapy (interval debulking)\n* Completed first-line platinum-based chemotherapy and surgery with a response, in the opinion of the Investigator\n* Sufficient tumor tissue for planned analysis\n* ECOG performance status of 0 or 1\n* Patients must be 20 years of age to consent in Japan, Taiwan and South Korea; in all other participating countries patients must be 18 years of age to consent\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Pure sarcomas or borderline tumors or mucinous tumors\n* Active second malignancy\n* Known central nervous system brain metastases\n* Any prior treatment for ovarian cancer, other than the first-line platinum regimen\n* Evidence of interstitial lung disease or active pneumonitis\n* Active, known or suspected autoimmune disease\n* Condition requiring active systemic treatment with either corticosteroids (>10 mg daily prednisone equivalent) or other immunosuppressive medications",
    "miscellaneous_criteria": ""
}